{"protocolSection":{"identificationModule":{"nctId":"NCT06471946","orgStudyIdInfo":{"id":"VAHCT2024"},"organization":{"fullName":"Navy General Hospital, Beijing","class":"OTHER"},"briefTitle":"VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS","officialTitle":"Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-09-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2029-09-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2030-09-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-17","studyFirstSubmitQcDate":"2024-06-18","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-06-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Liren Qian","investigatorTitle":"Vice Director","investigatorAffiliation":"Navy General Hospital, Beijing"},"leadSponsor":{"name":"Navy General Hospital, Beijing","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.","detailedDescription":"The investigators will evaluate 2 year overall survival(OS) after transplantation in patients with higher-risk MDS. Progression free survival (PFS), incidence of acute GVHD, non-relapse mortality (NRM), graft-versus-host disease (GVHD)-free relapse-free survival(GRFS), and incidence of chronic GVHD at 1 and 2 years after transplantation will be counted."},"conditionsModule":{"conditions":["Higher-risk Myelodysplastic Syndromes"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":54,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT","type":"EXPERIMENTAL","description":"Patients were treated by Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT","interventionNames":["Drug: Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT"]}],"interventions":[{"type":"DRUG","name":"Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT","description":"Patients were treated by VA Conditioning Regimen Allo-HSCT:\n\nVenetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9","armGroupLabels":["Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT"],"otherNames":["VA Conditioning Regimen Allo-HSCT"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival","description":"OS was defined as time from diagnosis to death from any cause or the last follow-up","timeFrame":"3 year"}],"secondaryOutcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"3 year"},{"measure":"Incidence of acute GVHD and chronic GVHD","timeFrame":"3 year"},{"measure":"Non-relapse mortality (NRM)","timeFrame":"3 year"},{"measure":"Graft-versus-host disease (GVHD)-free relapse-free survival(GRFS)","timeFrame":"3 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.\n* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* The patient should be diagnosed with higher risk MDS according to the standard criteria of the World Health Organization (WHO).\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"70 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Liren Qian, PhD","role":"CONTACT","phone":"+861066947192","email":"qlr2007@126.com"}],"overallOfficials":[{"name":"Liren Qian, PhD","affiliation":"Navy General Hospital, Beijing","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Navy General Hospital","city":"Beijing","state":"Beijing","zip":"100048","country":"China","contacts":[{"name":"Liren Qian, M.D.","role":"CONTACT","phone":"+861066957676","email":"qlr2007@126.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000011289","term":"Preleukemia"},{"id":"D000009190","term":"Myelodysplastic Syndromes"},{"id":"D000013577","term":"Syndrome"}],"ancestors":[{"id":"D000004194","term":"Disease"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000001855","term":"Bone Marrow Diseases"},{"id":"D000006402","term":"Hematologic Diseases"},{"id":"D000011230","term":"Precancerous Conditions"},{"id":"D000009369","term":"Neoplasms"}],"browseLeaves":[{"id":"M16355","name":"Syndrome","asFound":"Syndrome","relevance":"HIGH"},{"id":"M12145","name":"Myelodysplastic Syndromes","asFound":"Myelodysplastic Syndrome","relevance":"HIGH"},{"id":"M14164","name":"Preleukemia","asFound":"Myelodysplastic Syndrome","relevance":"HIGH"},{"id":"M5134","name":"Bone Marrow Diseases","relevance":"LOW"},{"id":"M9490","name":"Hematologic Diseases","relevance":"LOW"},{"id":"M14111","name":"Precancerous Conditions","relevance":"LOW"},{"id":"T3993","name":"Myelodysplastic Syndromes","asFound":"Myelodysplastic Syndrome","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001374","term":"Azacitidine"},{"id":"C000579720","term":"Venetoclax"}],"ancestors":[{"id":"D000000964","term":"Antimetabolites, Antineoplastic"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M249656","name":"Venetoclax","asFound":"Stage III","relevance":"HIGH"},{"id":"M4673","name":"Azacitidine","asFound":"Resistance","relevance":"HIGH"},{"id":"M4281","name":"Antimetabolites","relevance":"LOW"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}